NYSE:GEN Genesis Healthcare (GEN) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free GEN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.45▼$24.1550-Day Range$0.18▼$0.6052-Week Range$0.40▼$1.37Volume9.05 million shsAverage Volume4.10 million shsMarket Capitalization$15.34 billionP/E Ratio26.67Dividend Yield2.08%Price Target$26.00 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSocial MediaStock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSocial Media Genesis Healthcare MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside8.3% Upside$26.00 Price TargetShort InterestN/ADividend StrengthModerateBased on Four FactorsSustainabilityN/ANews Sentiment0.00Based on 19 Articles This WeekInsider TradingN/AProj. Earnings Growth5.52%From $1.63 to $1.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.82 out of 5 starsBusiness Services Sector255th out of 314 stocksPrepackaged Software Industry173rd out of 203 stocks 1.3 Analyst's Opinion Consensus RatingGenesis Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGenesis Healthcare has only been the subject of 1 research reports in the past 90 days.Read more about Genesis Healthcare's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GEN. Previous Next 2.5 Dividend Strength Dividend YieldGenesis Healthcare pays a meaningful dividend of 3.05%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenesis Healthcare does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genesis Healthcare is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Genesis Healthcare will have a dividend payout ratio of 29.07% next year. This indicates that Genesis Healthcare will be able to sustain or increase its dividend.Read more about Genesis Healthcare's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GEN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 19 news articles for Genesis Healthcare this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for GEN on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows5 people have added Genesis Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genesis Healthcare insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Genesis Healthcare is held by insiders.Percentage Held by Institutions82.08% of the stock of Genesis Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Genesis Healthcare's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Genesis Healthcare are expected to grow by 5.52% in the coming year, from $1.63 to $1.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genesis Healthcare is 26.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Genesis Healthcare is 26.67, which means that it is trading at a less expensive P/E ratio than the Business Services sector average P/E ratio of about 32.89. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover About Genesis Healthcare Stock (NYSE:GEN)Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2020, it provided inpatient services through a network of approximately 341 skilled nursing facilities and assisted/senior living communities in 24 states; and supplied rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 42 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.Read More Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover GEN Stock News HeadlinesMay 13 at 10:08 PM | finance.yahoo.comStream Companies selected as Genesis Certified Digital Advertising VendorMay 11 at 7:06 PM | finance.yahoo.comGen Digital Full Year 2024 Earnings: EPS Misses ExpectationsMay 11 at 9:18 AM | msn.comCoshocton Public Health starts Coffee with a Doc seriesMay 10 at 5:45 PM | fool.comWhy Gen Digital Stock Zoomed 15% Higher TodayMay 10 at 5:31 AM | msn.comGreater QC Hispanic Chamber presents Multicultural Speaker SeriesMay 9, 2024 | reuters.comGen Digital beats quarterly revenue estimatesMay 9, 2024 | prnewswire.comGen Delivers Fifth Consecutive Year of Organic Growth and Record Profitability in Fiscal 2024May 8, 2024 | bizjournals.comCounty slashes rare incentives for Rodney Steven-linked Goddard housing projectMay 8, 2024 | msn.comNew study offers insight into genesis of spina bifidaMay 8, 2024 | finance.yahoo.comGenesis Unveils Emerging Technology, HOCl Atomizing, for 'Air Quality Awareness Week'May 7, 2024 | msn.comMental Health Minister Matt Doocey sought advice on ‘social impact bonds’ to fund servicesMay 7, 2024 | finance.yahoo.comStork Club Reproductive Care Benefits Expands its Centers of Excellence Provider Network with GENESIS Fertility & Reproductive MedicineMay 7, 2024 | msn.comIndegene IPO subscribed 1.67 times on Day 1 of offerMay 5, 2024 | msn.com24-hour tennis marathon raises more than $15K for coach battling cancerMay 2, 2024 | msn.com2025 Genesis GV80 Coupe reviewMay 2, 2024 | msn.com2025 Genesis GV80 reviewMay 2, 2024 | tmcnet.comJumptuit Launches Genesis J2T AI Global Risk Visibility Spectrum Dashboard Detecting Probable Geopolitical and Environmental EventsMay 2, 2024 | finance.yahoo.comCommunity Healthcare Trust Inc (CHCT) (Q1 2024) Earnings Call Transcript Highlights: Robust ...April 30, 2024 | msn.com2025 Genesis GV80 price and specsApril 30, 2024 | finance.yahoo.comGENESIS AND GENESIS INSPIRATION FOUNDATION CONTRIBUTE OVER $100,000 TO SAVANNAH COMMUNITYApril 29, 2024 | finance.yahoo.comGen Supports Local Communities During Global Volunteer WeekApril 27, 2024 | msn.comGenesis Coshocton Medical Center is recognized for patient careApril 26, 2024 | yahoo.comPrince Harry and Meghan Markle ‘in informational blackout’ with Kate, Charles’ health updates: expertApril 26, 2024 | finance.yahoo.comCelebrating Earth Month With Team GenApril 24, 2024 | msn.comGenesis Recalls More Vehicles That May Lose Power While DrivingSee More Headlines Company Calendar Ex-Dividend for 3/13 Dividend2/15/2024Dividend Payable3/13/2024Last Earnings5/09/2024Today5/13/2024Dividend Payable6/12/2024Fiscal Year End3/31/2025Ex-Dividend for 6/12 Dividend1/01/2100Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorBusiness Services Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:GEN Previous SymbolNYSE:SKH CUSIPN/A CIK1351051 Webwww.genesishcc.com Phone610-444-6350Fax302-636-5454Employees2,700Year FoundedN/APrice Target and Rating Average Stock Price Target$26.00 High Stock Price Target$28.00 Low Stock Price Target$25.00 Potential Upside/Downside+10.8%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.90 Trailing P/E Ratio26.07 Forward P/E Ratio14.39 P/E GrowthN/ANet Income$836 million Net Margins17.83% Pretax Margin23.69% Return on Equity155.48% Return on Assets9.12% Debt Debt-to-Equity Ratio7.50 Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual Sales$2.80 billion Price / Sales5.36 Cash Flow$2.79 per share Price / Cash Flow8.42 Book Value($0.16) per share Price / Book-146.63Miscellaneous Outstanding Shares639,130,000Free Float618,038,000Market Cap$14.99 billion OptionableOptionable Beta0.84 Key ExecutivesMr. Robert H. Fish (Age 70)CEO & Director Comp: $411.5kMr. Thomas DiVittorio (Age 53)Exec. VP & CFO Comp: $565kMr. Paul David Bach (Age 62)COO & Exec. VP Comp: $630kMr. Stephen Scott Young (Age 49)Chief Accounting Officer & Treasurer Mr. Richard L. Castor (Age 66)Chief Information Officer & Sr. VP Mr. James W. Tabak (Age 62)Sr. VP of Admin. & Gov. Affairs Ms. Lori MayerVP of Investor Relations, Brand Management & Marketing CommunicationsMr. Michael Scott Sherman (Age 52)Sr. VP, Gen. Counsel, Sec. & Assistant Treasurer Mr. Larry BaiderSr. VP of People Strategy & OperationsDr. JoAnne Susan Reifsnyder R.N. (Age 62)Ph.D., Ph.D., ACHPN, MSN, MBA, RN, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer More ExecutivesKey CompetitorsDocuSignNASDAQ:DOCUUiPathNYSE:PATHElasticNYSE:ESTCDuolingoNASDAQ:DUOLProcore TechnologiesNYSE:PCORView All CompetitorsInsiders & InstitutionsCovestor LtdBought 466 shares on 5/11/2024Ownership: 0.001%Vanguard Group Inc.Sold 350,272 shares on 5/10/2024Ownership: 10.518%Mitsubishi UFJ Trust & Banking CorpBought 30,434 shares on 5/10/2024Ownership: 0.162%Intech Investment Management LLCBought 30,344 shares on 5/10/2024Ownership: 0.020%Twin Tree Management LPSold 12,255 shares on 5/10/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions GEN Stock Analysis - Frequently Asked Questions Should I buy or sell Genesis Healthcare stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GEN shares. View GEN analyst ratings or view top-rated stocks. What is Genesis Healthcare's stock price target for 2024? 5 brokers have issued 12-month target prices for Genesis Healthcare's stock. Their GEN share price targets range from $25.00 to $28.00. On average, they predict the company's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price. View analysts price targets for GEN or view top-rated stocks among Wall Street analysts. How were Genesis Healthcare's earnings last quarter? Genesis Healthcare, Inc. (NYSE:GEN) released its quarterly earnings results on Thursday, May, 9th. The company reported $0.48 earnings per share for the quarter, hitting analysts' consensus estimates of $0.48. The company earned $967 million during the quarter, compared to the consensus estimate of $965.03 million. Genesis Healthcare had a net margin of 17.83% and a trailing twelve-month return on equity of 155.48%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.46 earnings per share. How often does Genesis Healthcare pay dividends? What is the dividend yield for Genesis Healthcare? Genesis Healthcare declared a quarterly dividend on Thursday, May 9th. Stockholders of record on Monday, May 20th will be paid a dividend of $0.125 per share on Wednesday, June 12th. This represents a $0.50 dividend on an annualized basis and a yield of 2.08%. The ex-dividend date is Friday, May 17th. Read our dividend analysis for GEN. Is Genesis Healthcare a good dividend stock? Genesis Healthcare (NYSE:GEN) pays an annual dividend of $0.50 per share and currently has a dividend yield of 3.05%. The dividend payout ratio is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GEN will have a dividend payout ratio of 29.07% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for GEN. What ETFs hold Genesis Healthcare's stock? ETFs with the largest weight of Genesis Healthcare (NYSE:GEN) stock in their portfolio include Global X Cybersecurity ETF (BUG), Amplify Cybersecurity ETF (HACK), First Trust Nasdaq Cybersecurity ETF (CIBR), ASYMshares ASYMmetric S&P 500 ETF (ASPY), First Trust S&P 500 Diversified Dividend Aristocrats ETF (RNDV), Invesco S&P 500 Equal Weight Technology ETF (RYT), VictoryShares Nasdaq Next 50 ETF (QQQN) and Invesco S&P 500 Equal Weight Technology ETF (RSPT). How will Genesis Healthcare's stock buyback program work? Genesis Healthcare declared that its board has approved a stock repurchase plan on Thursday, May 9th 2024, which permits the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 23.1% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its stock is undervalued. What guidance has Genesis Healthcare issued on next quarter's earnings? Genesis Healthcare updated its first quarter 2025 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of 0.520-0.540 for the period, compared to the consensus EPS estimate of 0.530. The company issued revenue guidance of $960.0 million-$970.0 million, compared to the consensus revenue estimate of $965.6 million. What other stocks do shareholders of Genesis Healthcare own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genesis Healthcare investors own include Flaherty & Crumrine Preferred Securities Income Fund (FFC), Vaxart (VXRT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AT&T (T), Amarin (AMRN), Government Properties Income Trust (GOV), Advanced Micro Devices (AMD), Bausch Health Companies (BHC) and Who are Genesis Healthcare's major shareholders? Genesis Healthcare's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.52%), LSV Asset Management (0.78%), Mirae Asset Global Investments Co. Ltd. (0.32%), Swiss National Bank (0.27%), Sumitomo Mitsui Trust Holdings Inc. (0.25%) and Los Angeles Capital Management LLC (0.23%). Insiders that own company stock include Natalie Marie Derse and Ondrej Vlcek. View institutional ownership trends. This page (NYSE:GEN) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding Genesis Healthcare, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.